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Background
Epithelial to mesenchymal transition (EMT) is charac-
terised by the acquisition of a mesenchymal, motile 
pheno  type and is accompanied by characteristic molecu  lar 
changes, including the cadherin switch that is a hall  mark 
of EMT. Th   is switch in expression from junction-forming 
E-cadherin to the motility promoting N-cadherin is 
induced by transcriptional regulators such as Twist and 
Snail [1]. In addition, alternative splicing of mRNA pre-
cursors can also inﬂ  uence EMT [2].
Th   e cell–cell and cell–matrix adhesion molecule CD44 
is highly susceptible to alternative splicing as the CD44
gene spans 20 coding exons, 10 of which are variantly 
expressed. Generally, expression of CD44 variant iso-
forms (CD44v) is common in epithelial cells, while the 
standard isoform (CD44s), with all variant exons excised, 
is expressed by haematopoietic and mesenchymal cells. 
Alternative splicing of CD44 is known to be deregulated 
during pathological processes including tumour invasion 
and metastasis, but evidence for a correlation of tumour 
behaviour with the diﬀ  erent CD44v is sparse and can be 
contradictory [3]. As the last steps of tumour progression 
require dynamic adhesive properties from a cell, switch-
ing between an adhesive state and a motile state is 
fundamental for successful metastasis formation. EMT 
and its postulated reversion are crucial processes in-
volved in this cellular plasticity.
Article
In a recent article, Chonghui Cheng’s laboratory demon-
strated a functional role for CD44 alternative splicing 
during EMT [4]. Several nontumorigenic epithelial cell 
lines were used for EMT induction with diﬀ  erent EMT 
triggers. In all cases this induction was accompanied by a 
switch in CD44 isoform expression from CD44v to 
CD44s and, using a variety of approaches, was demon-
strated to be essential for EMT. Importantly, the overall 
level of CD44 protein did not change signiﬁ  cantly during 
this process. Isoform speciﬁ  city of this eﬀ  ect was con-
ﬁ  rmed using RNA interference and rescue experi  ments, 
and clearly demonstrated that expression of CD44s, and 
not loss of CD44v, was required for cells to undergo EMT 
in these systems. Mechanistically, strong data were 
provided highlighting the role of the epithelial-speciﬁ  c 
splicing factor ESRP1. Expression of ESRP1 was down-
regu  lated during EMT, leading to reduced CD44v 
expression and increased CD44s levels. Furthermore, 
CD44s expres  sion, but not CD44v expression, was 
function  ally linked to Akt activa  tion, upregulation of 
anti-apoptotic mole  cules and apop  tosis resistance.
Th   ese studies were then extended to a mouse model of 
breast cancer recurrence and a small cohort of human 
breast tumour samples, which revealed a correlation of 
CD44s expression with recurrent and high-grade breast 
cancer, respectively, as well as with a mesenchymal 
pheno type.
Viewpoint
Th   e important ﬁ  nding of this article is the functional role 
of CD44s expression during EMT. CD44 isoform 
switching and the involvement of the splice factor ESRP1 
have been described previously [5-7], but the data 
presented by Brown and colleagues signiﬁ  cantly extend 
these studies by clearly demonstrating a causal role for 
CD44 isoform switching in EMT and suggesting CD44s 
as the main substrate for ESRP1 during EMT [4]. Th  e 
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promotes EMT by demon  strating that only CD44s 
expression is associated with Akt activation in this 
system. As all CD44 isoforms share a common cyto-
plasmic domain, these data suggest that isoform-speciﬁ  c 
signalling during EMT should involve diﬀ  erential inter-
actions of the CD44 extracellular domain. CD44 can 
interact with the microenvironment in multiple ways – 
for example, via acting as a co-receptor for trans  mem-
brane receptors like c-Met or by mediating interactions 
with the extracellular matrix via binding to its principle 
ligand hyaluronan [8], which has been previously 
implicated in EMT promotion. In MDCK and MCF-10A 
cells, hyaluronan synthase-2 expression induces EMT 
and activates the phosphoinositide 3-kinase/Akt pathway 
[9]. Further, in a model of ﬁ  brosis-associated EMT, TNFα 
was shown to induce transcriptional upregulation of 
CD44 and its subsequent pericellular interaction with 
hyaluronan, leading to cell–cell dissociation and cellular 
motility [10]. In this respect, it would be of interest to 
determine the potential role played by TNFα and other 
external factors in ESRP1 regulation.
Alternative splicing is known to be deregulated during 
tumour progression [11], and CD44v expression has been 
repeatedly linked to metastasis formation.  Brown and 
colleagues linked switching to the CD44s isoform with 
tumour recurrence in the HER2/Neu mouse model [4]. 
Although the data presented are of interest, in our view 
the chosen mouse model has limitations for the study of 
breast cancer progression as it does not recapitulate well 
the human situation. Recurrent and secondary breast 
cancers usually have a very similar phenotype to the 
primary tumour, arguing for EMT during invasion and 
metastasis to be transient in nature. In the small cohort 
of human breast tumours examined, CD44s expression 
correlated with a high-grade N-cadherin-positive pheno-
type. Future studies with larger patient cohorts will be 
required to assess the diagnostic value of this observation 
and to determine whether Akt activation is indeed linked 
to CD44s expression in tumour samples.
Both EMT and high CD44 expression have been 
ascribed to cells with tumour-initiating properties, so-
called cancer stem cells, in breast cancer and other 
carcinomas [8,12]. Importantly, Brown and colleagues’ 
article addresses a potential functional role for CD44s in 
cancer stem cells by promoting EMT and induction of 
apoptosis resistance [4]. As the overall protein level of 
CD44 did not change during EMT, these data will 
encourage researchers to examine CD44 isoform 
speciﬁ  city rather than focusing on high expression levels.
Together, these ﬁ  ndings argue for the epithelial pheno-
type to be actively maintained by attenuating CD44s 
expression at the expense of producing alternatively 
spliced variants. Th   e demonstration that overexpression 
of ESRP1 was able to block the splicing switch and 
maintain an epithelial phenotype raises the question of 
whether upregulating ESRP1 levels in mesenchymal cells 
could restore an epithelial phenotype. Th  is hypothesis 
has the intriguing therapeutic possibility of normalising a 
highly potent metastatic cell by reversing EMT.
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